Generic QNASL Availability
QNASL (beclomethasone dipropionate - aerosol, metered;nasal)
Manufacturer: TEVA BRANDED PHARM
Approval date: March 23, 2012
Strength(s): 0.08MG/ACTUATION [RLD]
Manufacturer: TEVA BRANDED PHARM
Approval date: December 17, 2014
Has a generic version of QNASL been approved?
No. There is currently no therapeutically equivalent version of QNASL available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of QNASL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Medicinal aerosol formulations
Issued: November 4, 1997
Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
Assignee(s): Riker Laboratories, Inc.
A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.Patent expiration dates:
- November 4, 2014✓
- November 4, 2014
Beclomethasone solution aerosol formulations
Issued: July 7, 1998
Inventor(s): Schultz; Robert K. & Schultz; David W.
Assignee(s): Minnesota Mining and Manufacturing Company
Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.Patent expiration dates:
- July 7, 2015✓
- July 7, 2015
Dispensing apparatus with dosage counter
Issued: August 24, 2010
Inventor(s): Ingram; Simon & Campling; Nick & Bradley; Duncan
Assignee(s): Consort Medical plc
A dispensing apparatus (1) comprising a housing containing a dosage counter comprising at least two annular members (11, 13) and a cog (12), each being mounted rotationally. The housing is suitable for receiving, in use, a container (1) containing a product for dispensation. Each actuation of the apparatus causes the first annular member to incrementally rotate which, after a predetermined number of actuations of the apparatus, causes the cog to rotate, the rotation of the cog causing the second annular member to incrementally rotate.Patent expiration dates:
- January 24, 2027✓
- January 24, 2027
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 23, 2015 -
- December 17, 2017 -
- QNASL Consumer Information (Drugs.com)
- Qnasl aerosol Consumer Information (Wolters Kluwer)
- Qnasl Consumer Information (Cerner Multum)
- QNASL Advanced Consumer Information (Micromedex®)
- Beclomethasone aerosol Consumer Information (Wolters Kluwer)
- Beclomethasone spray Consumer Information (Wolters Kluwer)
- Beclomethasone nasal Consumer Information (Cerner Multum)
- Vancenase Advanced Consumer Information (Micromedex®)
- Vancenase AQ Double Strength Advanced Consumer Information (Micromedex®)
- Beclomethasone Nasal Advanced Consumer Information (Micromedex®)
- Beclomethasone Dipropionate eent AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|